Industry News

Teladoc’ s victory in federal court. LEWISVILLE, Texas---- Teladoc, Inc., the nation’ s first and largest telehealth provider, today announced the U.S. Patent and Trademark Office has invalidated the major elements of a telemedicine patent held by American Well Corporation on the basis that they were not patentable because American Well did not invent them."/>
Teladoc Secures Second Consecutive Win in Patent Dispute
Atossa Genetics Inc. today announced a reverse split of its common stock at a ratio of 1- for-15, effective August 26, 2016, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2016. The reverse split was approved by the Company's stockholders at an annual meeting of the stockholders held on May 18, 2016. The Company's common stock will continue to trade on the NASDAQ Capital Market under the..."/>
Atossa Genetics Announces Reverse Stock Split
Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman& CEO, and Sean Whelan, CFO, will present at four upcoming investor conferences. Whelan are scheduled to participate in the Robert W. Baird 2016 Healthcare Conference in New York on Wednesday, September 7, 2016 at 10:50 AM ET. Whelan are scheduled to participate in the Wells Fargo 2016 Healthcare Conference in Boston on Thursday, September 8, 2016..."/>
Diplomat to Participate in Upcoming Investor Conferences - Diplomat
Medovex Corp., a developer of medical technology products, announced today that it has added orthopedic industry veteran Ron Lawson to its Board of Directors. Ron Lawson's 35 plus years of experience in the orthopedic industry include the role as Senior Vice President of Worldwide Sales and Customer Service for Pfizer's Orthopedic Division, Howmedica. In 1998, he became part of the Stryker Corporation with Stryker's acquisition of Howmedica."/>
Medovex Corporation Adds 35 Year Orthopedic Industry Veteran Ron Lawson to Board of Directors
Shanghai Pharmaceuticals Released 2016 Interim Results
Medtronic PLC reported lower adjusted net income for the quarter ended July 29, but higher-than-expected earnings per share from sales of medical devices. Adjusted net income dropped to $1.44 billion, down 1 percent from the same period last year at the Minnesota-run maker of advanced medical devices and healthcare supplies. The comparison to last year's net income was complicated because the same quarter a year ago included an extra week of sales."/>
Medtronic beats forecasts on earnings, despite lower net income [Star Tribune (Minneapolis)]
Mylan NV by striking down two patents held by Israel-based Teva Pharmaceutical Industries Ltd for its blockbuster drug Copaxone 40 mg/mL formulation. "The US PTO has ruled in favor of Mylan in its inter partes review proceeding and found all claims of two related Copaxone 40 mg patents to be unpatentable," Natco said in a statement."/>
US patent office rules in favour of Natco Pharma's US partner Mylan [Mint, New Delhi]
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that it has been awarded a contract for up to $13.2 million in total funding from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority for the development and commercialization of the Company’ s rapid POC Zika test and..."/>
Chembio Awarded Up to $13.2 Million U.S. Government Contract to Develop and Commercialize Point-of-Care Tests for Zika Virus
Nix® Launches First-Ever Lice Tracker
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it will present at five investor conferences in September. On Wednesday, September..."/>
Merit Medical to Present at Five Conferences
Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants initially exercisable to purchase an aggregate of 24,000,000 shares of common stock with a public offering price of $25.00 for a combination of one share of Series B Convertible Preferred Stock and a warrant to..."/>
Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million
OneSavings Bank said it will continue to focus on what it does best. In an interim update the challenger bank said underlying pre-tax profit was pounds sterling 64.6 m in the first six months of the year, up 36 pc on the same period a year ago. Assets on its books have grown 20.8 pc to pounds sterling 6.3 bn."/>
Daily Mail, London, market report column [Daily Mail, London]
Halyard Health, Inc. and Kimberly-Clark Corporation on behalf of investors who purchased or otherwise acquired Kimberly-Clark securities on or after February 25, 2013 and received Halyard securities in connection with Kimberly-Clark’ s spin-off of Halyard in October..."/>
Kessler Topaz Meltzer & Check, LLP Announces Final Deadline Reminder for Halyard Health, Inc. and Kimberly-Clark Corporation Shareholders
MannKind Corporation announced that the United States District Court for the Central District of California has dismissed the class action that was pending against MannKind Corporation and two of its executives. The Court granted the defendants’ motion to dismiss the plaintiffs’ amended class action complaint without leave to amend, thereby closing the case. The plaintiffs can appeal the decision within 30 days.."/>
Securities Class Action Against MannKind Dismissed
Capstone Therapeutics Corp. and LipimetiX Development, Inc., the Company’ s drug development joint venture announced today that the JV’ s Series B-1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing. Evolution Venture Partners, a NY-based investment bank, has been engaged to advise the JV on corporate finance matters."/>
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
Propanc Health Group Corporation, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations and public relations programs. KCSA will deploy a..."/>
Propanc Retains KCSA Strategic Communications as Investor Relations and Public Relations Counsel
OptimizeRx Corp., a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.. OptimizeRx CEO William Febbo is scheduled to present on Wednesday, September 7 at 8:30 a.m. Pacific time, with one-on-one meetings held throughout..."/>
OptimizeRx to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
Akorn, Inc., a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. About Ofloxacin Otic Solution Ofloxacin Otic Solution is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:. Otitis Externa in adults and pediatric patients, 6 months..."/>
Akorn Relaunches Ofloxacin Otic Solution
Simulations Plus, Inc., the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released version 1.0 of PKPlus, its next-generation software for analysis of preclinical and clinical trial data. Mark Pflieger, product manager for PKPlus, said:“ More than two years in the making, we..."/>
Simulations Plus Releases PKPlus™ Version 1.0
Baxter’ s industry-leading AMIA APD system with SHARESOURCE, REVACLEAR high-flux dialyzer and CRRT products. DEERFIELD, Ill.---- Baxter International Inc., a global leader in renal care, and Satellite Healthcare, a leading, national not-for-profit and the sixth largest provider of patient-centered dialysis and kidney..."/>
Baxter and Satellite Healthcare Partner to Bring Innovative Dialysis Care to More Patients
Bioanalytical Systems, Inc., a recognized global leader in the development of instrumentation for automated blood sampling in animal models, is proud to announce its launch of the Embrace Automation grant program featuring the BASi Culex NxT™ Automated Blood Sampling system and Raturn™. As laboratory techniques and instrumentation evolved, many formerly manual processes became automated— from basic pipetting to intricate high-throughput..."/>
BASi Launches Embrace Automation Grant Program with Culex NxT™ Automated Blood Sampling System

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary591 Articles
Information Technology555 Articles
Financials462 Articles
Health Care331 Articles
Industrials329 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at